Alumis Inc. (ALMS) Stock Score, Valuation & Financial Research
Alumis Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 20/100.
Quick answer for ALMS
Alumis Inc. currently has a Wall Street Score of 20/100. The stored market price is $7.94. Its financial score is 7/100. Its valuation score is 0/100. The latest WSS change is +0.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Alumis Inc. does
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS financial snapshot
- Wall Street Score:
- 20/100
- Current price:
- $7.94
- Market capitalization:
- $980.1M
- Revenue:
- $7.4M
- Net income:
- $-439.0M
- Free cash flow:
- $-370.2M
- Cash:
- $63.7M
- Total debt:
- $36.4M
- EPS:
- -3.80
- Financial score:
- 7/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.7%.
- Free cash flow is $-370.2M, showing cash burn in the current stored period.
- The balance sheet shows $63.7M of cash versus $36.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.7 points: ALMS increased 0.7 points because Asset improved by 6.5 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 7/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALMS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.